Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation

Experimental Dermatology

Volumn 18, Issue 3, 2009, Pages 246-251

  Lerche, Catharina M ^a   Philipsen, Peter A ^a   Poulsen, Thomas ^b   Wulf, Hans Christian ^a  

^a Mental Health Services CPH   (Denmark)

^b Sonderborg Hospital   (Denmark)

Author keywords

Calcineurin inhibitors; Photocarcinogenesis; Pimecrolimus; Tacrolimus; Ultraviolet radiation

Indexed keywords

PIMECROLIMUS; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGEN TESTING; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; ERYTHEMA; FEMALE; HAIRLESS MOUSE; MOUSE; NONHUMAN; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; SKIN CARCINOGENESIS; SOLAR RADIATION; TREATMENT DURATION; ULTRAVIOLET A RADIATION;

ADMINISTRATION, TOPICAL; ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, HAIRLESS; NEOPLASMS, RADIATION-INDUCED; SKIN; SKIN NEOPLASMS; SKIN PIGMENTATION; TACROLIMUS; ULTRAVIOLET RAYS;

EID: 64549135493     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00812.x     Document Type: Article

References (29)

1. Thaci D, Salgo R. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: A safety update. Acta Dermatovenerol Alp Panonica Adriat 2007: 16: 58-62.
2. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 2001: 144: 507-513.
3. Ring J, Barker J, Behrendt H et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: Position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005: 19: 663-671.
4. Kyllonen H, Remitz A, Mandelin J M, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004: 150: 1174-1181.
5. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998: 111: 396-398.
6. Food and Drug Administration. Available at http://www.fda.gov/medwatch/ safety/2006/Elidel_DHCP_%201-27-06.pdf. 2008.
7. Food and Drug Administration. Available at http://www.fda.gov/medwatch/ safety/2006/protopic_DHCP_2-1-06.pdf. 2008.
8. Ormerod A D. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005: 153: 701-705.
9. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007: 16: 385-393.
10. Ashcroft D M, Chen L C, Garside R, Stein K, Williams H C. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007: 4: CD005500.
11. Forbes P D. Relevance of animal models of photocarcinogenesis to humans. Photochem Photobiol 1996: 63: 357-362.
12. Simon G A, Maibach H I. Relevance of hairless mouse as an experimental model of percutaneous penetration in man. Skin Pharmacol Appl Skin Physiol 1998: 11: 80-86.
13. Lerche C M, Philipsen P A, Poulsen T, Wulf H C. Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 2008: 17: 57-62.
14. Autier P. Perspectives in melanoma prevention: The case of sunbeds. Eur J Cancer 2004: 40: 2367-2376.
15. Diffey B L, Jansen C T, Urbach F, Wulf H C. The standard erythema dose: a new photobiological concept. Photodermatol Photoimmunol Photomed 1997: 13: 64-66.
16. Bech-Thomsen N, Poulsen T, Christensen F G, Lundgren K, Wulf H C. UVA tanning devices interact with solar-simulated UV radiation in skin tumor development in hairless mice. Arch Dermatol Res 1992: 284: 353-357.
17. Wulf H C, Poulsen T, Brodthagen H, Hou-Jensen K. Sunscreens for delay of ultraviolet induction of skin tumors. J Am Acad Dermatol 1982: 7: 194-202.
18. Hedelund L, Lerche C, Wulf H C, Haedersdal M. Carcinogenesis related to intense pulsed light and UV exposure: An experimental animal study. Lasers Med Sci 2006: 21: 198-201.
19. Hansen A B, Bech-Thomsen N, Wulf H C. In vivo estimation of pigmentation in ultraviolet-exposed hairless mice. Photodermatol Photoimmunol Photomed 1995: 11: 14-17.
20. Petersen A B, Na R, Wulf H C. Sunless skin tanning with dihydroxyacetone delays broad-spectrum ultraviolet photocarcinogenesis in hairless mice. Mutat Res 2003: 542: 129-138.
21. Matsui M S, Deleo V A. Longwave ultraviolet radiation and promotion of skin cancer. Cancer Cells 1991: 3: 8-12.
22. Cole C A, Forbes P D, Davies R E. An action spectrum for UV photocarcinogenesis. Photochem Photobiol 1986: 43: 275-284.
23. Available at http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2006:265:0039:0043:EN:PDF. 2008.
24. Ring J, Mohrenschlager M, Henkel V. The US FDA 'Black Box' Warning for topical calcineurin inhibitors: An ongoing controversy. Drug Saf 2008: 31: 185-198.
25. Tran C, Lubbe J, Sorg O et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005: 211: 341-347.
26. Doelker L, Tran C, Gkomouzas A et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006: 15: 342-346.
27. Gambichler T, Schlaffke A, Tomi N S, Othlinghaus N, Altmeyer P, Kreuter A. Tacrolimus ointment neither blocks ultraviolet B nor affects expression of thymine dimers and p53 in human skin. J Dermatol Sci 2008: 50: 115-122.
28. Taieb A. Tacrolimus and the pigmentary system. Dermatology 2005: 210: 177-178.
29. Kang H Y, Choi Y M. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 2006: 155: 1037-1040.